However, no agreement on pre-emptive transplantation has been reached yet, even though patients with FA with highest risks of AML or MDS may have the indication for an upfront transplant before disease progression, as exemplified by carriers of FANCD1/BRCA2 mutations [81]. This evidence concerns the gene BRCA2 and acute myeloid leukemia.